ProMIS Neurosciences (PMN) Income from Continuing Operations (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Income from Continuing Operations came in at 8716455.0 in Q1 2026, down 16.84% YoY from 10481682.79 in Q1 2025, and up 83.18% on a QoQ basis from 51810532.0 in Q4 2025.
ProMIS Neurosciences (PMN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Income from Continuing Operations data on file, last reported at 8716455.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 16.84% year-over-year to 8716455.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 82462080.0 (down 298.5% YoY) and the FY2025 annual result came in at 81205721.0, down 66.71% from the prior year.
- Income from Continuing Operations grew to 8716455.0 in Q1 2026, from 51810532.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2592953.0 in Q3 2023 to a low of 51810532.0 in Q4 2025.
- A 5-year average of 8536079.65 and a median of 4998940.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 57.2% — and 2025, when it slumped 763.16%.
- Tracing PMN's Income from Continuing Operations over 5 years: stood at 8522610.0 in 2022, then surged by 53.64% to 3951432.0 in 2023, then slumped by 51.91% to 6002445.0 in 2024, then tumbled by 763.16% to 51810532.0 in 2025, then jumped by 83.18% to 8716455.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8716455.0 (Q1 2026), 51810532.0 (Q4 2025), and 11750432.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | -12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.40 Mn |
| Mar 31, 2026 | -8.72 Mn |
| Dec 31, 2025 | -51.81 Mn |
| Sep 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -10.18 Mn |
| Mar 31, 2025 | -7.46 Mn |
| Dec 31, 2024 | -6.00 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Sep 30, 2023 | -2.59 Mn |
| Jun 30, 2023 | -2.95 Mn |
| Mar 31, 2023 | -4.97 Mn |
| Dec 31, 2022 | -8.52 Mn |
| Sep 30, 2022 | -6.06 Mn |
| Jun 30, 2022 | -5.00 Mn |
| Mar 31, 2022 | -4.09 Mn |
| Dec 31, 2021 | -4.69 Mn |
| Sep 30, 2021 | -2.21 Mn |